Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers

COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort inc...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 9; no. 11; p. 1223
Main Authors Alqassieh, Rami, Suleiman, Aiman, Abu-Halaweh, Sami, Santarisi, Abeer, Shatnawi, Omar, Shdaifat, Lara, Tarifi, Amjed, Al-Tamimi, Mohammad, Al-Shudifat, Abdel-Ellah, Alsmadi, Heba, Al Sharqawi, Ahmed, Alnawaiseh, Hadeel, Anasweh, Yara, Domaidah, Farah Abo, Jaber, Haneen Abu, Al-Zarir, Mohammad Rashid, Bsisu, Isam
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 21.10.2021
MDPI
Subjects
Adaptive immunity
Antibodies
antibody
Antigens
Cardiovascular diseases
Comparative studies
Confidence intervals
Coronaviruses
COVID-19
COVID-19 vaccines
Enzymes
Immunoglobulin G
Immunoglobulins
Pfizer-BioNTech
Phosphatase
Proteins
Regression analysis
Severe acute respiratory syndrome coronavirus 2
Sinopharm
Statistical analysis
titers
vaccine
Vaccines
Viral diseases
United States > US
COVID-19
Pfizer-BioNTech
Sinopharm
vaccine
antibody
titers
Online AccessGet full text

Cover

Abstract COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
AbstractList COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG ( p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects ( p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25–196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11–0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG ( < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects ( < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25-196.15; = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11-0.99; = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25-196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11-0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific antibodies in subjects vaccinated with either the Pfizer-BioNTech COVID-19 vaccine or the Sinopharm vaccine. This prospective observational cohort included Jordanian adults vaccinated with two doses, 21 days apart, of either of the two aforementioned vaccines. Titers were collected 6 weeks after the administration of the second dose. Overall, 288 participants were included, of which 141 were administered the Pfizer-BioNTech vaccine, while 147 were administered the Sinopharm vaccine. Remarkably, 140 (99.3%) of the Pfizer-BioNTech vaccine recipients had positive IgG titers, while 126 (85.7%) of Sinopharm recipients had positive IgG (p < 0.001). The mean titer for IgG among Pfizer-BioNTech recipients was 515.5 ± 1143.5 BAU/mL, compared to 170.0 ± 230.0 BAU/mL among Sinopharm subjects (p < 0.001). Multivariable regression analysis showed that the Pfizer-BioNTech vaccine positively correlated with positive IgG titers (OR: 25.25; 95% CI: 3.25-196.15; p = 0.002), compared with a negative effect of cardiovascular diseases (OR: 0.33; 95% CI: 0.11-0.99; p = 0.48) on IgG titers. In conclusion, fully vaccinated recipients of the Pfizer-BioNTech vaccine had superior quantitative efficiency compared to Sinopharm recipients. A booster dose is supported for Sinopharm recipients, or those with chronic immunosuppressive diseases.
Author Suleiman, Aiman
Jaber, Haneen Abu
Bsisu, Isam
Alqassieh, Rami
Al Sharqawi, Ahmed
Al-Shudifat, Abdel-Ellah
Anasweh, Yara
Al-Zarir, Mohammad Rashid
Santarisi, Abeer
Alnawaiseh, Hadeel
Shdaifat, Lara
Abu-Halaweh, Sami
Alsmadi, Heba
Shatnawi, Omar
Tarifi, Amjed
Al-Tamimi, Mohammad
Domaidah, Farah Abo
AuthorAffiliation 7 Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan; mohammad.altamimi@hu.edu.jo (M.A.-T.); amalmufleh@hotmail.com (A.-E.A.-S.)
2 Beth Israel Deaconess Medical Center, Anesthesia and Intensive Care Department, Harvard Medical School, Boston, MA 02215, USA; Asuleima@bidmc.harvard.edu
3 Department of Anesthesia and Intensive Care, School of Medicine, The University of Jordan, Amman 11942, Jordan; s.halaweh@ju.edu.jo (S.A.-H.); Sw006999@gmail.com (H.A.); sharqawiahmed@gmail.com (A.A.S.); Hanabrklna@gmail.com (H.A.); Yara.anasweh@gmail.com (Y.A.); farahabodomaidah@gmail.com (F.A.D.); abujaber.haneen@gmail.com (H.A.J.); rashed.zaareer@gmail.com (M.R.A.-Z.)
1 Department of General and Specialized Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan; Rami_qaisieh@yahoo.com (R.A.); amjed.tarifi@gmail.com (A.T.)
5 Department of Cancer Biology, Wake Forest School of Medicine and Wake Forest Baptist Health, Winston-Salem, NC 27157, USA; Omar.juve10@gmail.com
4 D
AuthorAffiliation_xml – name: 4 Department of Emergency Medicine and Accidents, School of Medicine, The University of Jordan, Amman 11942, Jordan; abeer_santarisi@yahoo.com
– name: 3 Department of Anesthesia and Intensive Care, School of Medicine, The University of Jordan, Amman 11942, Jordan; s.halaweh@ju.edu.jo (S.A.-H.); Sw006999@gmail.com (H.A.); sharqawiahmed@gmail.com (A.A.S.); Hanabrklna@gmail.com (H.A.); Yara.anasweh@gmail.com (Y.A.); farahabodomaidah@gmail.com (F.A.D.); abujaber.haneen@gmail.com (H.A.J.); rashed.zaareer@gmail.com (M.R.A.-Z.)
– name: 5 Department of Cancer Biology, Wake Forest School of Medicine and Wake Forest Baptist Health, Winston-Salem, NC 27157, USA; Omar.juve10@gmail.com
– name: 6 School of Medicine, Mutah University, Karak 61710, Jordan; Shdaifatlara@gmail.com
– name: 1 Department of General and Specialized Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan; Rami_qaisieh@yahoo.com (R.A.); amjed.tarifi@gmail.com (A.T.)
– name: 7 Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan; mohammad.altamimi@hu.edu.jo (M.A.-T.); amalmufleh@hotmail.com (A.-E.A.-S.)
– name: 2 Beth Israel Deaconess Medical Center, Anesthesia and Intensive Care Department, Harvard Medical School, Boston, MA 02215, USA; Asuleima@bidmc.harvard.edu
Author_xml – sequence: 1
  givenname: Rami
  orcidid: 0000-0002-0270-0436
  surname: Alqassieh
  fullname: Alqassieh, Rami
– sequence: 2
  givenname: Aiman
  orcidid: 0000-0003-2625-4028
  surname: Suleiman
  fullname: Suleiman, Aiman
– sequence: 3
  givenname: Sami
  surname: Abu-Halaweh
  fullname: Abu-Halaweh, Sami
– sequence: 4
  givenname: Abeer
  surname: Santarisi
  fullname: Santarisi, Abeer
– sequence: 5
  givenname: Omar
  orcidid: 0000-0002-2304-8969
  surname: Shatnawi
  fullname: Shatnawi, Omar
– sequence: 6
  givenname: Lara
  surname: Shdaifat
  fullname: Shdaifat, Lara
– sequence: 7
  givenname: Amjed
  orcidid: 0000-0001-8519-9431
  surname: Tarifi
  fullname: Tarifi, Amjed
– sequence: 8
  givenname: Mohammad
  orcidid: 0000-0001-7486-4192
  surname: Al-Tamimi
  fullname: Al-Tamimi, Mohammad
– sequence: 9
  givenname: Abdel-Ellah
  surname: Al-Shudifat
  fullname: Al-Shudifat, Abdel-Ellah
– sequence: 10
  givenname: Heba
  surname: Alsmadi
  fullname: Alsmadi, Heba
– sequence: 11
  givenname: Ahmed
  surname: Al Sharqawi
  fullname: Al Sharqawi, Ahmed
– sequence: 12
  givenname: Hadeel
  surname: Alnawaiseh
  fullname: Alnawaiseh, Hadeel
– sequence: 13
  givenname: Yara
  surname: Anasweh
  fullname: Anasweh, Yara
– sequence: 14
  givenname: Farah Abo
  surname: Domaidah
  fullname: Domaidah, Farah Abo
– sequence: 15
  givenname: Haneen Abu
  surname: Jaber
  fullname: Jaber, Haneen Abu
– sequence: 16
  givenname: Mohammad Rashid
  surname: Al-Zarir
  fullname: Al-Zarir, Mohammad Rashid
– sequence: 17
  givenname: Isam
  orcidid: 0000-0002-8999-8334
  surname: Bsisu
  fullname: Bsisu, Isam
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34835153$$D View this record in MEDLINE/PubMed
BookMark eNp1kstrGzEQxpeS0qRpzr2VhV562Uav1aOHgmv6CIQ2EDf0Jma1UiyzllxpbUj_-sp2UhJDdZGY-eY3H5p5WR2FGGxVvcboPaUKnW_AGB9sVhhjQuiz6oQgwRuq6K-jR-_j6iznBSpHYSq5eFEdUyZpi1t6Ut1cOf_HpuaTj99n1sxrCH197UNczSEtP9STehqXK0gw-o2tr8d1f1fHUF_FPDY3u_4lUwKTMPouluTMjzblV9VzB0O2Z_f3afXzy-fZ9Ftz-ePrxXRy2Rgmxdh0kgBumeKcYss613VEGS6MUxQUdgYjosBRCQIDU8IZjqFn0Lm275lqO3paXey5fYSFXiW_hHSnI3i9C8R0qyGN3gxWO-m4JLwlHQiGmJDOgeupMhR3WBhRWB_3rNW6W9re2DAmGJ5An2aCn-vbuNGSE4TkFvDuHpDi77XNo176bOwwQLBxnTXhiCHCBJJF-vZAuojrFMpXbVVlmErytqjePHb0z8rD-Iqg3QtMijkn67Tx424gxaAfNEZ6uyn6YFNK3flB3QP6fxV_ASIswqA
CitedBy_id crossref_primary_10_1371_journal_pone_0306457
crossref_primary_10_1016_j_vaccine_2023_01_032
crossref_primary_10_3390_vaccines10122002
crossref_primary_10_3389_fimmu_2022_940357
crossref_primary_10_1016_j_micpath_2022_105729
crossref_primary_10_47993_gmb_v46i2_664
crossref_primary_10_3390_vaccines10030465
crossref_primary_10_1016_j_jiac_2022_12_009
crossref_primary_10_3390_vaccines11030637
crossref_primary_10_1002_jmv_29231
crossref_primary_10_3390_diagnostics13030556
crossref_primary_10_3390_ijms232315415
crossref_primary_10_1016_j_biologicals_2023_101668
crossref_primary_10_3389_fpubh_2023_1092425
crossref_primary_10_47671_TVG_78_22_112
crossref_primary_10_3390_vaccines11091398
crossref_primary_10_3390_vaccines10020303
crossref_primary_10_1093_cid_ciac288
crossref_primary_10_3390_antib11020038
crossref_primary_10_3390_vaccines11010051
crossref_primary_10_4103_ijcm_ijcm_477_22
crossref_primary_10_1080_21645515_2022_2088966
crossref_primary_10_1080_21645515_2023_2184754
crossref_primary_10_1371_journal_pone_0274526
crossref_primary_10_3390_vaccines10050692
crossref_primary_10_1016_j_vaccine_2023_01_029
crossref_primary_10_3390_vaccines11030684
crossref_primary_10_47993_gmb_v46i2_777
crossref_primary_10_3390_vaccines11010056
crossref_primary_10_3889_oamjms_2023_11163
crossref_primary_10_1186_s12879_022_07069_z
crossref_primary_10_3390_vaccines10050643
crossref_primary_10_1111_irv_70053
crossref_primary_10_59748_ot_v8i15_147
crossref_primary_10_3389_fimmu_2022_992370
crossref_primary_10_3390_microorganisms13010135
crossref_primary_10_1093_cei_uxac113
crossref_primary_10_1371_journal_pone_0281689
crossref_primary_10_3389_fimmu_2022_919408
crossref_primary_10_1016_j_advnut_2023_06_003
crossref_primary_10_1177_03946320221133697
crossref_primary_10_1016_j_heliyon_2023_e21877
crossref_primary_10_1136_bmjopen_2023_071789
crossref_primary_10_1016_j_msard_2023_104761
crossref_primary_10_3389_fimmu_2022_817597
crossref_primary_10_3389_fimmu_2024_1448408
crossref_primary_10_3233_HAB_240029
crossref_primary_10_3390_vaccines10081340
crossref_primary_10_3389_fimmu_2024_1382911
crossref_primary_10_4239_wjd_v14_i6_892
Cites_doi 10.1111/j.1574-695X.1999.tb01397.x
10.2139/ssrn.3823718
10.1093/labmed/lmab032
10.4049/jimmunol.2000526
10.1038/s41591-021-01325-6
10.1093/cid/ciaa344
10.1093/cid/ciaa676
10.1101/2021.03.03.21251066
10.11613/BM.2020.030901
10.1093/cvr/cvaa106
10.1016/0090-1229(88)90188-2
10.1016/j.ebiom.2020.102763
10.1016/j.cca.2021.04.006
10.1016/j.arth.2020.04.055
10.1016/j.eclinm.2021.101018
10.3390/microorganisms9020245
10.3390/scipharm89010006
10.3389/fimmu.2021.704773
10.1038/s42003-021-01649-6
10.1001/jama.2021.3370
10.3390/vaccines9040365
10.3390/diagnostics11071135
10.1038/s41467-020-16256-y
10.1101/2021.07.15.21260362
10.1126/science.abc2241
10.1001/jama.2021.8565
10.1002/ajh.26185
10.1136/bmj.n1445
10.1007/s10787-021-00811-0
10.3390/ijerph18105111
10.1001/jamanetworkopen.2020.10895
10.1002/jmv.25727
10.1080/22221751.2021.1953403
10.1038/s41591-021-01377-8
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
NPM
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines9111223
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Journals
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (subscription)
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Engineering Research Database
ProQuest Central Student
Research Library Prep
ProQuest SciTech Premium Collection
Biological Sciences
Research Library (subscription)
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

Publicly Available Content Database
PubMed
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_f8f682652ba740478ffafd39c31b17c7
PMC8620087
34835153
10_3390_vaccines9111223
Genre Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Deanship of Scientific Research at the Hashemite University
  grantid: 639/2021
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
3V.
NPM
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c487t-b82a15496631e4bfbb29c67cf93a91fc1029af38a71a497fc61ad4abf5dd495b3
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:30:21 EDT 2025
Thu Aug 21 14:29:28 EDT 2025
Tue Aug 05 10:44:05 EDT 2025
Fri Jul 25 10:34:36 EDT 2025
Thu Jan 02 22:45:20 EST 2025
Tue Jul 01 02:25:00 EDT 2025
Thu Apr 24 22:58:33 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords COVID-19
Pfizer-BioNTech
Sinopharm
vaccine
antibody
titers
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c487t-b82a15496631e4bfbb29c67cf93a91fc1029af38a71a497fc61ad4abf5dd495b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0270-0436
0000-0003-2625-4028
0000-0001-7486-4192
0000-0001-8519-9431
0000-0002-8999-8334
0000-0002-2304-8969
OpenAccessLink https://doaj.org/article/f8f682652ba740478ffafd39c31b17c7
PMID 34835153
PQID 2602239865
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_f8f682652ba740478ffafd39c31b17c7
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8620087
proquest_miscellaneous_2604024708
proquest_journals_2602239865
pubmed_primary_34835153
crossref_citationtrail_10_3390_vaccines9111223
crossref_primary_10_3390_vaccines9111223
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211021
PublicationDateYYYYMMDD 2021-10-21
PublicationDate_xml – month: 10
  year: 2021
  text: 20211021
  day: 21
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Vaccines (Basel)
PublicationTitleAlternate Vaccines (Basel)
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Li (ref_23) 2020; 92
Berbudi (ref_25) 2020; 16
Zitt (ref_12) 2021; 12
Rubin (ref_39) 2021; 325
ref_34
ref_11
ref_32
ref_31
Gambino (ref_9) 2021; 52
Favresse (ref_38) 2021; 10
ref_17
Ebinger (ref_36) 2021; 27
Vitiello (ref_3) 2021; 29
Demonbreun (ref_19) 2021; 38
Geerlings (ref_26) 1999; 26
Guzik (ref_27) 2020; 116
Nagappa (ref_35) 2020; 71
Terpos (ref_22) 2021; 96
Khoury (ref_18) 2021; 27
Dogan (ref_15) 2021; 4
Gambino (ref_10) 2020; 30
Rathore (ref_13) 2020; 205
ref_21
ref_20
Wang (ref_6) 2020; 11
Liu (ref_29) 2020; 55
ref_2
Torjesen (ref_1) 2021; 373
Jacofsky (ref_8) 2020; 35
Zhang (ref_16) 2021; 326
Wu (ref_30) 2020; 3
ref_28
Zhao (ref_24) 2020; 71
Wu (ref_5) 2020; 368
Padoan (ref_37) 2021; 519
ref_4
Turner (ref_14) 1988; 46
ref_7
Tavaziva (ref_33) 2020; 370
References_xml – volume: 26
  start-page: 259
  year: 1999
  ident: ref_26
  article-title: Immune dysfunction in patients with diabetes mellitus (DM)
  publication-title: FEMS Immunol. Med. Microbiol.
  doi: 10.1111/j.1574-695X.1999.tb01397.x
– ident: ref_21
  doi: 10.2139/ssrn.3823718
– ident: ref_32
– volume: 52
  start-page: 493
  year: 2021
  ident: ref_9
  article-title: Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19
  publication-title: Lab Med.
  doi: 10.1093/labmed/lmab032
– volume: 205
  start-page: 555
  year: 2020
  ident: ref_13
  article-title: Early Insights into Immune Responses during COVID-19
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.2000526
– volume: 27
  start-page: 981
  year: 2021
  ident: ref_36
  article-title: Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01325-6
– volume: 71
  start-page: 2027
  year: 2020
  ident: ref_24
  article-title: Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa344
– volume: 71
  start-page: 3016
  year: 2020
  ident: ref_35
  article-title: Seroconversion Rate and Diagnostic Accuracy of Serological Tests for Coronavirus 2019
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciaa676
– ident: ref_11
– ident: ref_20
  doi: 10.1101/2021.03.03.21251066
– volume: 30
  start-page: 030901
  year: 2020
  ident: ref_10
  article-title: Comparison of a rapid immunochromatographic test with a chemiluminescence immunoassay for detection of anti-SARS-CoV-2 IgM and IgG
  publication-title: Biochem. Med.
  doi: 10.11613/BM.2020.030901
– volume: 116
  start-page: 1666
  year: 2020
  ident: ref_27
  article-title: COVID-19 and the cardiovascular system: Implications for risk assessment, diagnosis, and treatment options
  publication-title: Cardiovasc. Res.
  doi: 10.1093/cvr/cvaa106
– volume: 16
  start-page: 442
  year: 2020
  ident: ref_25
  article-title: Type 2 Diabetes and its Impact on the Immune System
  publication-title: Curr. Diabetes Rev.
– volume: 46
  start-page: 258
  year: 1988
  ident: ref_14
  article-title: Peripheral blood mononuclear cell abnormalities and their relationship to clinical course in homosexual men with HIV infection
  publication-title: Clin. Immunol. Immunopathol.
  doi: 10.1016/0090-1229(88)90188-2
– volume: 55
  start-page: 102763
  year: 2020
  ident: ref_29
  article-title: Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2020.102763
– volume: 519
  start-page: 60
  year: 2021
  ident: ref_37
  article-title: Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
  publication-title: Clin. Chim. Acta
  doi: 10.1016/j.cca.2021.04.006
– volume: 35
  start-page: S74
  year: 2020
  ident: ref_8
  article-title: Understanding Antibody Testing for COVID-19
  publication-title: J. Arthroplast.
  doi: 10.1016/j.arth.2020.04.055
– volume: 38
  start-page: 101018
  year: 2021
  ident: ref_19
  article-title: Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.101018
– ident: ref_34
  doi: 10.3390/microorganisms9020245
– ident: ref_28
  doi: 10.3390/scipharm89010006
– volume: 12
  start-page: 704773
  year: 2021
  ident: ref_12
  article-title: The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.704773
– volume: 4
  start-page: 129
  year: 2021
  ident: ref_15
  article-title: SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-01649-6
– volume: 325
  start-page: 1241
  year: 2021
  ident: ref_39
  article-title: COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough
  publication-title: JAMA
  doi: 10.1001/jama.2021.3370
– ident: ref_2
  doi: 10.3390/vaccines9040365
– ident: ref_4
– ident: ref_7
  doi: 10.3390/diagnostics11071135
– volume: 370
  start-page: m2516
  year: 2020
  ident: ref_33
  article-title: Diagnostic accuracy of serological tests for COVID-19: Systematic review and meta-analysis
  publication-title: BMJ
– volume: 11
  start-page: 2251
  year: 2020
  ident: ref_6
  article-title: A human monoclonal antibody blocking SARS-CoV-2 infection
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-16256-y
– ident: ref_17
  doi: 10.1101/2021.07.15.21260362
– volume: 368
  start-page: 1274
  year: 2020
  ident: ref_5
  article-title: A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
  publication-title: Science
  doi: 10.1126/science.abc2241
– volume: 326
  start-page: 35
  year: 2021
  ident: ref_16
  article-title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial
  publication-title: JAMA
  doi: 10.1001/jama.2021.8565
– volume: 96
  start-page: E257
  year: 2021
  ident: ref_22
  article-title: Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine
  publication-title: Am. J. Hematol.
  doi: 10.1002/ajh.26185
– volume: 373
  start-page: n1445
  year: 2021
  ident: ref_1
  article-title: COVID-19: Delta variant is now UK’s most dominant strain and spreading through schools
  publication-title: BMJ
  doi: 10.1136/bmj.n1445
– volume: 29
  start-page: 645
  year: 2021
  ident: ref_3
  article-title: Brief review of the mRNA vaccines COVID-19
  publication-title: Inflammopharmacology
  doi: 10.1007/s10787-021-00811-0
– ident: ref_31
  doi: 10.3390/ijerph18105111
– volume: 3
  start-page: e2010895
  year: 2020
  ident: ref_30
  article-title: Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2020.10895
– volume: 92
  start-page: 1518
  year: 2020
  ident: ref_23
  article-title: Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.25727
– volume: 10
  start-page: 1495
  year: 2021
  ident: ref_38
  article-title: Antibody titres decline 3-month post-vaccination with BNT162b2
  publication-title: Emerg. Microbes Infect.
  doi: 10.1080/22221751.2021.1953403
– volume: 27
  start-page: 1205
  year: 2021
  ident: ref_18
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01377-8
SSID ssj0000913867
Score 2.4094193
Snippet COVID-19 (coronavirus disease 2019) vaccines induce immunity through different mechanisms. The aim of this study is to compare the titers of specific...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1223
SubjectTerms Adaptive immunity
Antibodies
antibody
Antigens
Cardiovascular diseases
Comparative studies
Confidence intervals
Coronaviruses
COVID-19
COVID-19 vaccines
Enzymes
Immunoglobulin G
Immunoglobulins
Pfizer-BioNTech
Phosphatase
Proteins
Regression analysis
Severe acute respiratory syndrome coronavirus 2
Sinopharm
Statistical analysis
titers
vaccine
Vaccines
Viral diseases
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K33WbFBVK6CFurIclq7dNaAiFhoVuQm5Gki1qCHLIbgrbX58Z2dlHaOmlV0sGyTOjmc-a-YaQj8YHibTmeWGsySXX2ObFFbnVcFpW0gGiwOLk72fq9Fx-uywvN1p9YU7YQA88fLjDUAUFIXDJndUSqWRCsKERxgvmmPapjhx83gaYSmewYaJSeuDyEYDrD39ZjzfVczRuzsWWG0ps_X8KMR9mSm64npOn5MkYM9LJsNZn5FEbn5P96UA6vTygs3UN1fyA7tPpmo56-YJcTEP3u73Jj7r-DH-kUxsb-qOL_TVO-0In9HjNAE4xr3BJ-0ixi29-kbaThEcncdG5HgZnWLU8f0nOT77Ojk_zsZtC7gGULHJXcYt8bBBisFa64Bw3XmkfjLCGBQ-RhrFBVFYzK40OXjHbSOtC2TSAopx4RXZiH9s3hIqqUEYZqypAI8y6qhBlA3GEY8Ja73RGPt9_3NqPVOPY8eKqBsiB0qgfSCMjn1YvXA8sG3-feoTSWk1Deuz0AJSmHpWm_pfSZGT3Xtb1aLPzGpAdRzZEVWbkw2oYrA2vUGxs-9s0BwC31EWVkdeDaqxWIiREs-BAMqK3lGZrqdsjsfuZGL0BViI34Nv_sbd35DHHvBvwr5ztkp3FzW27B4HTwr1PNnIHGfYYag
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fb9MwELZge-EFwfgVGJOR0MTDwpLYiW1epnbaNCFRVdBNe4tsJx6RUFKaDqn89dwlbrpOwGvsSE7O9n3f-fwdIe-VdRxlzcNIaRXyRGCZFxOFWsBuKbkBRoGXk79MsotL_vk6vfYBt9anVa73xG6jLhqLMfJjwN0JatVl6cn8Z4hVo_B01ZfQeEh2YQuWQL52x2eT6dchyoKqlzITvaYPA35__EtbPLFucZEnCdtyR51q_9-g5v2MyTsu6PwJeeyxIx31xn5KHpT1Hjmc9uLTqyM629ylao_oIZ1uZKlXz8jV1FW_y0U4rpoJBtSprgv6raqbOXb7REf0dKMETjG_cEWbmmI13_Cq-5zOiHRULyvTQOMMby-3z8nl-dns9CL0VRVCC-RkGRqZaNRlA6gRl9w4YxJlM2GdYlrFzgLiUNoxqUWsuRLOZrEuuDYuLQpgU4a9IDt1U5evCGUyylSmdCaBlcTayIilBeAJEzOtrREB-bj-ubn1kuNY-eJHDtQDrZHfs0ZAPgwvzHu1jX93HaO1hm4ok909aBY3uV91uZMuA_6UJkYLjjpEzmlXMGVZbGJhYYD7a1vnfu22-WamBeTd0AyrDo9SdF02t10fIN5cRDIgL_upMYyEcUC14EgCIrYmzdZQt1vq6nun7A30EjUCX_9_WG_IowQza8CDJvE-2Vkubsu3AI2W5sDP_z-L2REd
  priority: 102
  providerName: ProQuest
Title Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
URI https://www.ncbi.nlm.nih.gov/pubmed/34835153
https://www.proquest.com/docview/2602239865
https://www.proquest.com/docview/2604024708
https://pubmed.ncbi.nlm.nih.gov/PMC8620087
https://doaj.org/article/f8f682652ba740478ffafd39c31b17c7
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdge-EF8U1gVEZCEw_LiGMnjpEQaqdNE9KqCtqpb5HtxCPSlIy2Q5S_njsnbelUJF7jS-T47nz388fvCHmnrBNIax5GSqtQxBLLvJgo1BJmy0wYQBR4OflimJ5PxJdpMt2UA-oGcL4T2mE9qcns-vjXj-VncPhPiDgBsn_4qS1uQs_RbyHa3Sf7EJYkeulFl-v7aVkxnvmKsjFg95ArPm2pfnZ9YytKeTL_XRno3YOUf0Wms0fkYZdS0n5rA4_JvbJ-Qg5HLSf18oiON1es5kf0kI42bNXLp-Ry5Krf5SwcVM0Q19mprgv6raqbGxT7SPv0ZEMQTvHY4ZI2NcUiv-Gl_x2vW9qvF5VpoHGMl5rnz8jk7HR8ch52xRZCC5hlEZos1kjXBhkIK4VxxsTKptI6xbVizkIiorTjmZZMCyWdTZkuhDYuKQoAWYY_J3t1U5cvCeVZlKpU6TQDsMK0ySKeFJBmGMa1tkYG5Hg1uLntmMixIMZ1DogEtZHf0UZA3q9fuGlJOP4tOkBtrcWQPds_aGZXeeeMuctcCrAqiY2WAumJnNOu4MpyZpi00MGDla7zlUXmAPxiJEtMk4C8XTeDM-IOi67L5tbLAB4XMsoC8qI1jXVPuIBkF-JLQOSW0Wx1dbulrr57wm9AnUgd-Or_h-E1eRDj4RsIsjE7IHuL2W35BrKnhemR_cHpcPS151cfet5H_gBwKRxu
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fb9MwELZG9wAviN90DDASTDwsW2K7cYyEUDs2dWyrKuimvQXbiVkllJSmA5U_ir-RuyRN6QS87TV2Isd3vrvPPn9HyEtlnUBac89XWnmCSSzzYnxPS7CWkTCAKPBy8skg7J-KD-ed8zXya3EXBtMqFzaxNNRJbnGPfBfiboZcdWHn3eSbh1Wj8HR1UUKjUoujdP4DIFvx9vA9yPcVYwf7o72-V1cV8CwE5zPPREwjLxm42iAVxhnDlA2ldYprFTgLHldpxyMtAy2UdDYMdCK0cZ0kATRhOHz3BlkXHKBMi6z39gfDj82uDrJsRqGsOIQ4V_7ud23xhLxAo8IYX3F_ZZWAv4W2VzM0_3B5B3fI7TpWpd1Kue6StTS7R7aGFdn1fJuOlne3im26RYdLGuz5fXI2dOOf6dTrjfMBbuBTnSX00zjLJ9jtDe3SvSXzOMV8xjnNM4rVg72z8ndKpaHdbDY2OTSO8LZ08YCcXst8PyStLM_Sx4TyyA9VqHQYAQoKtIl83kkgfjEB19oa2SY7i8mNbU1xjpU2vsYAdVAa8RVptMnr5oVJxe7x7649lFbTDWm5ywf59Etcr_LYRS4EvNZhRkuBvEfOaZdwZXlgAmlhgJsLWce1rSjipWa3yYumGVY5Ht3oLM0vyz4A9IX0ozZ5VKlGMxIuIIoGx9UmckVpVoa62pKNL0omcYCzyEm48f9hPSc3-6OT4_j4cHD0hNximNUD3psFm6Q1m16mTyEsm5ln9Vqg5PN1L7_ffsdO9A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anYR4mbhTGGAkmHhYaGKncYyEULut2hhUFXTT3jLbiaESSkrbgcpP49dxTpK2dALe9hq7lZNz_ezj7wA8V9aFRGvu-UorL-SS2rwY39MSvWUcGkQUdDn5Qz86PAnfnbXPNuDX4i4MlVUufGLpqNPC0h55C_NuTlx1Ubvl6rKIwX7v7fibRx2k6KR10U6jUpHjbP4D4dv0zdE-yvoF572D4d6hV3cY8Cwm6jPPxFwTRxmG3SALjTOGKxtJ65TQKnAWo6_STsRaBjpU0tko0GmojWunKSILI_B_r8GmRFTkN2Cze9AffFzu8BDjZhzJik9ICOW3vmtLp-VTcjCci7VQWHYM-Fuae7la84_w17sJW3XeyjqVot2CjSy_DTuDivh6vsuGq3tc0122wwYrSuz5HTgduNHPbOJ1R0WfNvOZzlP2aZQXY5r2mnXY3oqFnFFt45wVOaNOwt5p-TqlArFOPhuZAgeHdHN6ehdOruR734NGXuTZA2Ai9iMVKR3FiIgCbWJftFPMZUwgtLZGNuHV4uMmtqY7p64bXxOEPSSN5JI0mvBy-YNxxfTx76ldktZyGlF0lw-KyeektvjExS5C7NbmRqN-hDJ2TrtUKCsCE0iLC9xeyDqp_cY0WWl5E54th9Hi6RhH51lxUc5B0B9KP27C_Uo1lisRIWbUGMSaINeUZm2p6yP56EvJKo7QlvgJH_5_WU_hOppd8v6of_wIbnAq8MFAzoNtaMwmF9ljzNBm5kltCgzOr9r6fgPN-1Mp
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pfizer-BioNTech+and+Sinopharm%3A+A+Comparative+Study+on+Post-Vaccination+Antibody+Titers&rft.jtitle=Vaccines+%28Basel%29&rft.au=Alqassieh%2C+Rami&rft.au=Suleiman%2C+Aiman&rft.au=Abu-Halaweh%2C+Sami&rft.au=Santarisi%2C+Abeer&rft.date=2021-10-21&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=11&rft.spage=1223&rft_id=info:doi/10.3390%2Fvaccines9111223&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines9111223
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon